Opioid Medication Assisted Tx (1)

Slides:



Advertisements
Similar presentations
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Advertisements

PERMEATING BORDERS OVERDOSE PREVENTION Summer Conference 2014 July 24, 2014 ACOPC Allegheny County Overdose Prevention Coalition Presents.
Sublingual Buprenorphine and Pain
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Treating opioid addiction in hospitalized medical patients Miriam Komaromy, MD, FACP Associate Director, ECHO Institute.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
MEDICATION ASSISTED TREATMENT for OPIATE DEPENDENCY WHAT WORKS? SHELLEY ASKEW FLOYD, MS DIRECTOR OF PHARMACOTHERAPY SERVICES PYRAMID HEALTHCARE, INC.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Hazelden’s Comprehensive Opioid Response and Educational Solutions Death in the Suburbs: How Prescription Painkillers and Heroin have Changed Treatment.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Good Prescribing to support Criminal Justice Interventions
 Methadone is prescribed to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
VIVITROL INJECTIONS IN CONJUNCTION WITH THE WARREN COUNTY JAIL Coordination at many levels.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine.
Vivitrol (Naltrexone) Treatment for opioid addiction.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Medication Assisted Treatment for Opioid Use Disorders
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Presented by Caroline Waterman, MA, LRC, CRC, Executive Director, COMPA Sonia Lopez, MD, Medical Director, START Sarah Church, Ph.D., Executive Director,
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Addressing the issue: Prescription Drug Misuse in North Carolina
Gregory S. Brigham, Ph.D., CEO
Medical Assisted Treatment
Medication Assisted Treatment
Medication-Assisted Treatment
Treatment Access A Substance Use Disorder Perspective
The Highs and Lows of Relapse and Recovery in Opioid Use Disorder
Medication Assisted Treatment
Substance Abuse Treatment in the FQHC: Managing the Opioid Crisis
Tanner Nissly DO, Bob Levy MD FASAM, Michele Mandrich MSW, CMPE
Medi-cal covered inpt tx in SoCo?
Medication-Assisted Therapy at Coleman Profession Services
Pharmacology of Opioids (1)
Opioids – A Pharmaceutical Perspective on Prescription Drugs
MEDICATION ASSISTED TREATMENT for OPIATE ADDICTION
A State Targeted Response to the Opioid Crisis:
What Works? Evidence-Based Practices for Treating Opioid Use Disorder
Medication-Assisted Treatment 101: Breaking the Stigma
Bevin K. Shagoury, Communications & Education Director
Evaluation of California’s Hub and Spoke System
Opioids in Butte County
Maintenance Treatment
Ten Pearls for Medication Assisted Treatment of Opiate Use Disorders
NCBH MAT Learning Community
Sara Olack, MD, PhD Cecilia Lau, MD Advisor: Jane Gagliardi, MD
Employees Retirement System of Texas (ERS) Changing the Script
SIHC MAT PROGRAM Hafifa Shabaik, PhD, RN, Quality Measures RN/Program Coordinator Young Suh, MD Medical Director/Program Director Southern Indian Health.
Addiction Treatment Program North Canyon Medical Center
Michael C. White, MCJ
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Are you sick and tired of being sick and tired?
Medications used in Treatment of Alcohol and Drug Use Disorders
Strategic Initiatives to Address Opioid Overdose & Addiction
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Treating Opioid Use Disorder
Treatment of Opioid Use Disorder
Harm Reduction Approach to Treatment of All Substance Use Disorders
Presentation transcript:

Opioid Medication Assisted Tx (1) C.L.I.P.S. Taper or replace? Chronic, relapsing illness. Long-term medication tx often needed to prevent relapse. 14 wk RCT. Bup taper vs ongoing MAT. Less +UDOA, more abstinence in MAT grp. 11% taper completed trial vs 66% MAT. Similar results to other trials. JAMA 2014. Patients on opioid agonist tx will have physical dependence. This is not addiction. OUD is fatal disease. MAT is primary prevention for HIV/HCV and death! Available medications Buprenorphine/naloxone (Suboxone). Avg dose 8-16 mg qd. Opioid partial agonist (bup) combined with antagonist (naloxone) Can be prescribed from office after 8 hour training & DEA Waiver (X license) Methadone (MTD). Avg dose 80-120 mg qd. Full opioid agonist Must be prescribed from licensed methadone tx program Legal to rx outpt x3 days while pt is waiting to enter methadone tx program Naltrexone. Dose is 50 mg PO qd. Opioid antagonist. Daily PO or monthly depot injection (Vivitrol). Blocks intoxication and prevents physiologic dependence. Does this stuff actually work? MTD vs placebo or nonmed tx. MTD increased tx retention and reduced heroin use. RR 0.66. Cochrane 2009. Bup/nalox vs MTD or placebo. Bup better than placebo for retention and less +UDOA. MTD better than bup at retention but = at decreasing use. Cochrane 2014. Naltrexone. Better evidence for depot form. Better retention than placebo. Mixed evidence on less +UDOA. Which of these medications are covered by Medi-cal? All of them. Including brand names. Carved out to state Medi-cal. No TAR required for “opioid use disorder” Updated 1/16 K.Greer

Opioid Medication Assisted Tx (2) C.L.I.P.S. Benefits of bup/nalox over methadone Doesn’t appear to share methadone SE (prolonged QT, hyperalgesia, hypogonadism) Much less risk of respiratory depression. Less abuse potential. Patient-centered. Avoid treatment program associated stress, travel, “drug lifestyle.” Engages patients in primary care system Disadvantages of bup/nalox Similar SE to other opioids (constipation, nausea, headache) Less structure for complicated patient Acute pain requires knowledgeable provider (actually not very complex!) How to get your patients into MAT Bup/nalox: Currently at Vista word-of-mouth referral. Formalization forthcoming. Cash pay at SRTP & other private docs in community. Get yourself certified! Methadone: Santa Rosa Treatment Program. DAAC/REAP. Naltrexone: No special prescriber requirements. Rx away! Other considerations Must triage pts. Mild/mod OUD suitable for office tx with bup/nalox or naltrexone. Severe OUD likely needs treatment program oversight. Recommend all patients to engage in some form of behavioral tx Check out SAMHSA-funded Provider Clinical Support System for MAT (PCSS-MAT). Education, training, mentoring, resources, clinical tools. Addiction is NOT a sign of weakness. It is NOT TRUE that all anybody needs to kick addiction is to “be strong.” Recovery takes commitment every day, through treatment and beyond. (SAMHSA friends/family MAT fact sheet 2014) County funded outpt programs? Women’s Recovery Services, DAAC, California Human Development. More @ www.sonoma-county.org/health/services/addictiontreatment.asp